The next generation of antibody drug conjugates.

@article{Mack2014TheNG,
  title={The next generation of antibody drug conjugates.},
  author={Fiona Mack and Michael K. Ritchie and Puja Sapra},
  journal={Seminars in oncology},
  year={2014},
  volume={41 5},
  pages={
          637-52
        }
}
Antibody-drug conjugates (ADCs) represent a promising therapeutic modality for the clinical management of cancer. The recent approvals of brentuximab vedotin and ado-trastuzumab emtansine plus emerging data for many molecules in clinical trials highlight the potential for ADCs to offer new therapeutic options for patients. Currently, more than 30 ADCs are being evaluated in early- or late-stage clinical trials. Accordingly, much has been done to refine and transform the early-generation ADCs to… CONTINUE READING
Highly Cited
This paper has 24 citations. REVIEW CITATIONS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Antibody-drug conjugates—an emerging class of cancer treatment

British Journal of Cancer • 2016
View 4 Excerpts
Highly Influenced

Antibody drug conjugates

Biotechnology Letters • 2016
View 2 Excerpts